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Effects of n-3 fatty acids on renal function and renal prostaglandin E
metabolism. The present study was performed to investigate the effects
of dietary fish oil supplements on renal function and renal prostaglandin
(PG) E metabolism. The usual "western" diet of 10 healthy volunteers
(six female and 4 male) aged between 21 and 35 years was supplemented
with 6 gIday of n-3 polyunsaturated fatty acids [3.6 g of eicosapen-
taenoic acid (EPA) and 2.4 g of docosahexaenoic acid (DHA)] for six
weeks. Supine arterial blood pressure (BP) and heart rate (HR), renal
hemodynamics, renal excretory function and urinary excretion of PGE2
and PGE3 were determined before and at the end of the fish oil
supplementation period. No changes could be observed in BP and HR
while renal plasma flow (RPF), determined as the clearance of PAH,
significantly increased from 559 44 to 738 47 mI/mm (P < 0.001)
with the fish oil supplements. This was associated with a decrease in
renal vascular resistance from (8.11 0.54) . 10—2 to (6.37
0.38) lO_2 mm Hg. mm. ml (P < 0.01). Glomerular filtration rate
(GFR), determined as the clearance of inulin, increased from 97 3 to
107 3 mI/mm (P < 0.01), resulting in a decrease in filtration fraction
from an average of 0.19 0.01 to 0.15 0.01 (P < 0.01). This was
paralleled by an increase in urine volume (V) (13.8 0.9 vs. 12.2 1.0
mi/mm; P < 0.05), urinary excretion of inorganic phosphate (UPhOV;
20.6 2.0 vs. 16.9 2.0 moi/min; P < 0.05) and CH,o (9.6 0.6 vs.
8.5 0.7 mI/mm) in the presence of unchanged UNaV, UKV, U,V,
Cosm and CH 0/GFR determined during maximal water diuresis and
hypotonic (0.i5%) saline infusion. Urinary excretion of POE2 deter-
mined in the six female participants decreased with the fish oil supple-
ments (168.0 13.0 vs. 125.3 11.8 ng/24 hr; P <0.01), while urinary
excretion of POE3 averaged 6.9 0.8 ng/24 hr during control and
increased to 23.4 3.2 ng/24 hr (P < 0.01) with the n-3 fatty acid
supplements. Our study demonstrates that supplementation of a regular
"western" diet with EPA and DHA in the here chosen doses over six
weeks markedly affects renal hemodynamics, with increases in RPF
and GFR. In spite of an increased filtered load, unchanged electrolyte
excretion implies increased tubular reabsorption which may, at least in
part, be located in the diluting segments of the nephron. These renal
hemodynamic and tubular functional changes are associated with
quantitative and qualitative alterations in renal prostanoid metabolism.
However, the precise interrelationship between the alterations in renal
eicosanoid metabolism and the changes observed in renal hemodynam-
ics and renal excretory function remains to be established.
n-3 (also called omega-3) fatty acids are polyunsaturated fatty
acids with a double bond between the third and fourth carbon
atom from the methyl end of the acid. These fatty acids are
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scarce in a normal "western" diet, but make up a significant
portion of the fat in cold water fish [1]. Such fish oil supple-
ments have been shown to affect a variety of cardiovascular
functions. Thus, a decrease in arterial blood pressure and/or a
blunted response to the administration of exogenous angioten-
sin II have been reported [2—8]. The mechanisms of the cardio-
vascular effects of n-3 fatty acid supplements remain unclear.
Since prostaglandins, prostacyclin, thromboxane, leukotrienes
and other eicosanoids may be important modulators within the
cardiovascular system [9—11], speculations center around
changes in eicosanoid metabolism induced by the dietary inter-
vention as mediators of the observed changes.
In addition to the proposed effects of n-3 fatty acids within
the systemic circulation, detailed information about their effects
on renal hemodynamics in humans is not available to date.
Moreover, only scarce data exist on the effects of dietary n-3
fatty acids supplements on renal prostaglandin E (PGE) metab-
olism [12]. Lastly, it is at present unknown whether fish oil
supplements affect renal excretory function. Such an effect
could be mediated, among others, by alterations in renal
hemodynamics and/or renal POE metabolism.
In the present study, we have therefore investigated the
effects of a six week supplementation period with eicosapen-
taenoic (EPA) and docosahexaenoic acid (DHA) on renal
hemodynamics, PGE metabolism and excretory function in
normal volunteer subjects.
Methods
The study was performed in 10 healthy volunteers (six female
and four male subjects), aged between 21 and 35 years, who
were on a regular "western" diet containing approximately 160
mmol of sodium and 80 mmol of potassium/day. All volunteers
were studied twice, first during a control period and then again
following six weeks of dietary fish oil supplements. n-3 fatty
acids were administered as capsules (MaxEPA, Hull, UK)
given p.o. (20 capsules/day in divided doses) yielding doses of
3.6 g of eicosapentaenoic acid (EPA) and 2.4 g of docosa-
hexaenoic acid (DHA)/day. To further document compliance to
the study protocol, platelet aggregation was determined before
and at the end of the dietary supplementation period. In all ten
volunteers, platelet aggregation following ADP, 1 tmo1/ml of
platelet rich plasma (PRP), or collagen, 1 p.g/ml PRP, was
suppressed by an average of 18 and 16%, respectively, which is
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an expected effect following dietary fish oil supplementation
[13—15].
Arterial blood pressure was measured in the supine position
following a 30 minute rest, by using a Dinamap (1846 SX) device
over 30 minutes at one-minute intervals. Heart rates were taken
concomitantly using continuous ECG monitoring. Only the
values obtained during the last 15 minutes were averaged to
allow the volunteers to sufficiently adapt to the blood pressure
taking procedure.
Renal hemodynamics and renal excretory function were
assessed before and at the end of the n-3 fatty acid supplemen-
tation period. After overnight fasting, all subjects received 20
mi/kg body weight of water between 07.00 and 09.00 hours. This
was followed by a continuous infusion of hypotonic (0.45%; 77
mmollkg) saline at a rate of 0.25 ml• min' kg' body weight
from 09.00 until 11.00 hours. Urine was collected by voluntary
voiding during three 30-minute clearance periods from 09.30 to
10.00, 10.00 to 10.30, and 10.30 to 11.00 hours, respectively.
Venous blood for the determination of hematocrit (Hct), serum
chloride (Cl), PAH and inulin concentrations and serum osmo-
lality was drawn through an indwelling catheter in an anticubital
vein at the midpoint of each clearance period. Glomerular
filtration rate (GFR) was measured using the clearance of
intravenously administered inulin with a 5 g bolus, followed by
continuous infusion of a 2% inulin solution in a dose of 3
mi/mm. Renal plasma flow (RPF) was calculated as the clear-
ance of PAH. Using a 20% PAH solution, a saturation dose of
10 ml was administered, followed by a maintainance dose of 0.1
mi/mm which was given throughout the protocol. Renal blood
flow (RBF) was calculated as [RPF/(102- Hct)] . 10.
Filtration fraction (FF) was calculated as the quotient of GFR
and RPF for each clearance period. Renal vascular resistance
(RVR) was estimated as the quotient of mean arterial blood
pressure and RBF and expressed as mm Hg mm m1'.
Clearance of free water (CH,o) was calculated by the formula
CH2O = V — UosmV/Ssm
where V = urine flow, Uosm = urinary osmolality and Ssm =
serum osmolality. The clearance of chloride (Cr1) was calcu-
lated by the formula
Cc1 = UçV/S1
where U1 = urinary chloride concentration and S = serum
chloride concentration. Delivery of chloride beyond the proxi-
mal nephron to the distal tubules (distal delivery) and distal
fractional chloride absorption (DFACI) were estimated by clear-
ance methods and calculated as [(CH20 + C1)/GFR] . 10 and
[CH2O/(CHO + Cr1)], respectively. Thus, distal delivery is
expressed as the sum of the fraction of filtered chloride excreted
(C1/GFR) plus the fractional free water clearance (CH,o/GFR),
while the rate of generation of solute-free water (C,0) factored
by the amount of chloride delivered to the diluting segments
(CH,o + Cr1) is used to estimate DFACI. It should be empha-
sized that the assessment of tubular function with these indirect
clearance techniques depends on several assumptions which
have been described in detail elsewhere [16]. Of critical impor-
tance is the requirement that the formation of solute-free water
accurately represents distal tubular NaCI absorption. There-
fore, in the present study, experiments were performed under
conditions of maximal water diuresis and hypotonic volume
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Fig. 1. HPLC separation of PGE2 and PGEJ Acetonitril/0.02 M
KH2PO4; pH 3.95; 28/72; wave length 194 nm; column: Lichrosorp
RP-18 (see Methods for details).
expansion to suppress the release of antidiuretic hormone.
However, since water movement in the distal nephron may
occur even in the absence of antidiuretic hormone [17], it is
obvious that both clearance terms can only be approximations
of the delivery into the distal nephron and distal tubular
reabsorptive capacity.
Serum and urinary sodium and potassium concentrations
were determined by internal standard flame photometry, serum
and urinary chloride concentrations with a Corning chloride
meter. Serum and urinary concentrations of inulin, PAH and
inorganic phosphate were measured according to established
photometric methods. Serum and urinary osmolalities were
determined with a Knauer osmometer.
Twenty-four hour urines for the determination of immunore-
active PGE, and POE3 were collected before and at the end of
the dietary supplementation period and were stored frozen until
assay. Ten milliliter samples were acidified with citric acid to
pH 3.5 and extracted with 4 volumes of ethyl acetate. After
evaporation with nitrogen the dry residue was redissolved in 3
ml of H20 also adjusted to pH 3.5 and passed through a C18
cartrige preconditioned with 20 ml of methanol and acidified
H20. The cartriges were rinsed with 20 ml of H20, 20 ml of 10%
ethanol and 10 ml petrolether and prostaglandins were then
eluted with 20 ml ethyl acetate. The eluate was again dried
under nitrogen, dissolved in 0,5 ml H20:acetonitrile (72:28) and
subjected to HPLC. POE2 and POE3 were eluted isocratically
with 0.02 M KH2PO4 (acidified with phosphoric acid to pH








Fig. 2. Effect of the n-3fatty acid
supplements on mean arterial blood pressure
(BP), renal plasma flow (RPF), renal blood
flow (RBF), renal vascular resistance (RVR),
glomerular filtration rate (GFR), and filtration
fraction (FF). Given are the means SEM of
the control period (D) and following fish oil
FF supplementation (U).
Following evaporation with nitrogen, the fractions were sus-
pended in buffer and 100 d portions used for radioimmunoas-
say. All assays were performed in duplicate using the '25J-
PGE2-RIA kit from New England Nuclear (Dreieich, FRG).
POE3 was purchased from Cayman Chemical (Ann Arbor,
Michigan, USA). This assay system exhibits significant cross-
reactivity with PGE3. Thus, in our assay system, 50% displace-
ment was reached with 2.9 pg of PGE2 and 8.6 pg of PGE3.
Individual measurements of POE2 were corrected for recover-
ies which were determined by the addition of 3H-PGE2 into the
urine samples. PGE3 results were corrected by the mean
recovery rate of POE3 (74.7 3.8%) which was determined by
adding known amounts of cold PGE3 into urine samples.
Results are given as means SEM. Statistical analysis was
performed using the Wilcoxon matched-pairs signed rank test
[18].
Results
The fish oil capsules in the here given dose were tolerated
well except for a fishy taste experienced by all but two
volunteers. No adverse effects other than this could be noted.
Supine systolic and diastolic arterial BP during control was
110.6 1.9/60.1 1.3 mm Hg with an average mean pressure
0175.9 1.1 mm Hg and a mean heart rate of 69.2 2.8 min.
These parameters were found unchanged at the end of the
dietary intervention period and measured 110.7 2.4/63.5 2.9
mm Hg, 78.7 2.7mm Hg, and 68.1 3.5 min', respectively.
The effect of the n-3 fatty acid supplementation on mean
arterial BP, RPF, RBF, RVR, GFR, and FF is illustrated in
Figure 2. RPF measured 559 45 ml/min during control and
significantly increased by an average of 32% to 738 47 mI/mm
(P < 0.001) following the n-3 fatty acid supplements. Since
hematocrit remained unchanged, RBF paralleled these changes
in RPF and measured 950 82 and 1288 86 ml/min (P <
0.001), respectively. In the presence of unchanged arterial BP,
calculated RVR had thus decreased from an average of (8.11
0.54). 10—2 to (6.37 0.38). 102 mm Hg mm m1 (P <
0.01). GFR increased by an average of 10%, from 97 3 to 107
3 mi/mm (P < 0.01). The proportionally greater increase in
RPF as compared to GFR resulted in a fall in filtration fraction
from an average of 0.19 0.01 to 0.15 0.01 (P <0.01).
The effect of the n-3 fatty acid supplements on renal excre-
tory function during the three clearance periods is summarized
in Table 1. During the control period, urinary excretion of Na
(UNaV), K (UKV), and Cl (U1V) averaged 284 50, 132
24, and 224 56 mol/min, respectively. The dietary interven-
tion had no effect on these renal excretory parameters, which
measured 275 36 (UNaV), 152 18 (UKV), and 201 30
j.mol/min (UCIV), respectively. Consequently, osmolar clear-
ance was also unchanged by the dietary intervention (4.3 0.5
vs. 4.4 0.3 mI/mm). Urine volume (V; 13.8 0.9 vs. 12.2
1.0 mI/mm; P < 0.05), urinary excretion of inorganic phosphate
(UPhOSV) (20.6 2.0 vs. 16.9 2.0 mol/min; P < 0.05) and
CH20 (9.6 0.6 vs. 8.5 0.7 ml/min; P < 0.05) were increased
following the n-3 fatty acids. There was no difference in
fractional free water clearance [(CH20/GFR) . 1021, which aver-
aged 8.7 0.7 during control and 8.7 0.7 following the fish oil
supplements. Finally, distal delivery (11.0 1.0 vs. 10.5 0.8)
and DFACI (0.80 0.04 vs. 0.83 0.01) were not changed with
the dietary intervention.
Urinary excretion of PGE2 in the six female volunteers
averaged 168.0 13.0 ng/24 hr and decreased by 26% to 125.3
11.8 ng/24 hr (P < 0.01) following the fish oil supplements.
Concomitantly, UPGE3V was hardly detectable during control
(6.9 0.8 ng/24 hr) but was increased by the end of the
six-week dietary intervention (23.4 3.2 ng/24 hr; P < 0.01).
Excretion of total PGE (PGE2 and POE3) averaged 174.9
13.5, and was tentatively, however, not significantly, decreased
to 148.7 13.4 ng/24 hr by the end of the fish oil supplemen-
tation period.
Discussion
The present study demonstrates that, in healthy man, fish oil
supplements in the here given dose may be associated with a
decrease in renal vascular resistance in the presence of un-
changed systemic arterial blood pressure and heart rate. The
more pronounced increase in RBF as compared to GFR may
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Table 1. Effect of dietary n-3 fatty acid supplements on renal plasma flow (RPF), glomerular filtration rate (GFR), filtration fraction (FF),
urine volume (V) and urinary excretion of sodium (UNaV), potassium (UKV), chloride (U,V) and inorganic phosphate (UphO,V), the clearance
of chloride (Cr1), osmolar clearance (Cosm) and free water clearance (CH,o), fractional free water clearance [(CH29JGFR) 1021, distal fractional
chloride absorption ECH2O/(CH2O + Cc1)] and distal delivery [(CH2O + C1)/GFR] 10
Control Following n-3 fatty acids
Clearance period Clearance period
I II III Mean SEM I II III Mean SEM
RPF mI/mm 553 48 570 54 559 46 559 45 736 54 733 50 744 51 738 47C
GFR 94±7 93±5 102±7 97±3 103±6 108±4 112±6
mi/mm
FF 0.15 0.01 0.17 0.01 0.19 0.02 0.19 0.01 0.15 0.02 0.16 0.02 0.15 0.01 0.15 0.01l
" mI/mm 11.8 1.9 12.9 1.2 12.2 0.8 12.2 1.0 13.6 1.4 14.4 1.0 13.4 1.1 13.8 0.9
UNaV mol/min 287 46 281 51 290 59 284 50 261 34 275 40 289 37 275 36
UKV 124 24 144 29 129 21 132 24 122 17 144 19 158 16 152 18
j.uno!/min
U1V 189 50 226 59 257 60 224 56 177 26 197 34 228 34 201 30
/.unoI/min
U,0,V 17.1 2.7 15.3 2.1 16.8 1.7 16.9 2.0 17.2 1.9 22.0 2.1 22.5 2.6 20.6 2.o
j.unol/min
C1 mI/mm 2.0 0.5 2.2 0.6 2.5 0.6 2.2 0.5 1.7 0.2 1.9 0.3 2.1 0.3 1.9 0.3
Cosm 4.5 0.7 4.2 0.7 4.3 0.5 4.3 0.5 4.5 0.3 4.4 0.4 4.3 0.4 4.4 0.3
mi/mm
CH20 8.7 1.0 8.7 1.0 7.9 0.8 8.5 0.7 9.0 1.3 10.0 0.8 9.0 0.8 9.6 0.6
mi/mm
(CH20/GFR) . 10 9,5 1,2 8.3 1.2 7.8 0.7 8.7 0.7 8.9 1.1 9.3 0.6 8.0 0.6 8.7 0.7




11.9 1,6 11.5 1.1 10.0 0.7 11.0 1.0 10.6 1.2 11.1 0.8 10.0 0.8 10.5 0.8
GFR
Given are the individual and mean values of the three clearance periods during control and following six weeks of n-3 fatty acid supplements.
a p < 0.05, b p < 0.01, P < 0.001, as compared to control values
point to a preferential effect of the n-3 fatty acid supplements
upon efferent glomerular arteriolar resistance.
The mechanisms of the vasodilatory effect of n-3 fatty acid
supplements within the renal circulation remain unclear.
Changes in renal eicosanoid metabolism with alterations in
the balance of the vasodilatory prostacyclin and the vasocon-
strictor thromboxane remain a likely, however unproven,
explanation. With respect to intrarenal blood flow, endogenous
angiotensin II may act as a vasoconstrictor agent with a more
pronounced effect on efferent as compared to afferent renal
glomerular arterioles [19]. Moreover, it has recently been
shown that dietary fish oil supplements may be associated with
a blunted effect of exogenous angiotensin II on systemic arterial
blood pressure [21. It could therefore be speculated that a
functional angiotensin Il-antagonism within the renal circula-
tion may participate in the renal hemodynamic effect of dietary
fisn oil supplements.
In more detail, the increase in GFR observed in the present
study points to changes in transcapillary hydraulic pressure
and/or the ultrafiltration coefficient, that is, total surface area
and/or hydraulic permeability associated with the n-3 fatty acid
supplements [20]. At present it remains unclear whether these
changes would translate into beneficial effects on renal function
in long-term clinical studies. So far, controversial results with
n-3 fatty acids have been presented with respect to renal
function in a variety of experimental and clinical conditions
[21—25]. Our own study points to the fact that renal blood flow
and GFR may increase in humans on fish oil supplements.
However, these short-term effects should be interpreted cau-
tiously on the basis of the recently established association of
increased glomerular pressure, hyperfiltration and the devel-
opment and progression of renal insufficiency [261. Therefore,
renal function should be monitored in long-term studies, espe-
cially if n-3 fatty acids should be more widely used in the
therapeutic management of various disorders.
In spite of the marked changes in renal hemodynamics with a
pronounced increase in GFR, renal electrolyte excretion was
unchanged, suggesting renal tubular effects associated with the
fish oil supplements. The precise tubular localization of in-
creased solute reabsorption remains unclear. The clearance
techniques used in the present study did not reveal differences
with respect to the "distal delivery" term. In the presence of
increased GFR unchanged "distal delivery" as calculated in the
present study suggests that the proportion of filtered solute
reabsorbed proximal to the diluting segment was unchanged. In
absolute terms, it thus points to increased amounts of solutes
reaching the diluting segments. Increased urine volume and
urinary excretion of inorganic phosphate following the dietary
n-3 fatty acid supplementation, as observed in the present study
under conditions of maximal water diuresis, are compatible
with this finding. Consequently, unchanged solute excretion in
the presence of increased GFR is therefore most likely due to
increased reabsorption in the distal portion of the nephron. This
is tentatively supported by the slight increase in CM2O values
following the n-3 fatty acid supplements. With the reservations
that these type of clearance studies deserve, it may therefore be
concluded that dietary supplementation with n-3 fatty acids
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may affect the reabsorptive capacity within the diluting seg-
ments of the nephron.
To date, the effect of dietary fish oil supplements on renal
PGE metabolism has not been investigated systemically. In the
present study, n-3 fatty acid supplements were associated with
a significantly decreased urinary excretion rate of POE2. The
ability of the human kidney to form POE3 has been suggested in
a study using gas chromatography/mass spectrometry [27]. In
that study in three male volunteers, dietary supplements of 40
ml of cod liver oil for four weeks resulted in urinary PGE3
excretion rates of about 20% those of PGE2, while no POE3
could be detected in the urine of one control person not
receiving the n-3 fatty acid supplements. However, the results
of this study do not allow the conclusion that POE3 is formed in
human kidneys since urinary excretion of PGE in males may
not exclusively represent renal biosynthesis [28]. Therefore, the
demonstration of increased urinary excretion of immunoreac-
tive PGE3 in six female volunteers in the present study adds
further support to the notion that the human kidney may indeed
produce significant amounts of PGE3 during a high intake of n-3
fatty acids. Since PGE2 may be involved in the regulation of
tubular NaC1 absorption [29—31], it may be speculated that the
quantitative and qualitative changes in PGE biosynthesis could
participate, at least in part, in the alterations of tubular electro-
lyte absorption during a high intake of n-3 fatty acids.
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